{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T05:16:24Z","timestamp":1768713384619,"version":"3.49.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","immunology.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.iac.2015.04.004","type":"journal-article","created":{"date-parts":[[2015,7,23]],"date-time":"2015-07-23T02:30:24Z","timestamp":1437618624000},"page":"439-452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Eosinophilia in Hematologic Disorders"],"prefix":"10.1016","volume":"35","author":[{"given":"Lorenzo","family":"Falchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.iac.2015.04.004_bib1","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1056\/NEJM199805283382206","article-title":"Eosinophilia","volume":"338","author":"Rothenberg","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.iac.2015.04.004_bib2","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1365-2141.2006.06038.x","article-title":"Eosinophilia: secondary, clonal and idiopathic","volume":"133","author":"Tefferi","year":"2006","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.iac.2015.04.004_bib3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1586\/ehm.11.81","article-title":"Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field","volume":"5","author":"Valent","year":"2012","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.iac.2015.04.004_bib4","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1001\/archinte.163.11.1371-a","article-title":"Eosinophilia and diseases: clinical review of 1862 cases","volume":"163","author":"Lombardi","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.iac.2015.04.004_bib5","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1086\/322707","article-title":"Diagnosis of Strongyloides stercoralis infection","volume":"33","author":"Siddiqui","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.iac.2015.04.004_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jaci.2010.01.055","article-title":"Organ-specific eosinophilic disorders of the skin, lung, and gastrointestinal tract","volume":"126","author":"Simon","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2015.04.004_bib7","first-page":"411","article-title":"Eosinophilia in Addison's disease","volume":"49","author":"Spry","year":"1976","journal-title":"Yale J Biol Med"},{"issue":"9165","key":"10.1016\/j.iac.2015.04.004_bib8","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(99)01346-X","article-title":"Relative eosinophilia and functional adrenal insufficiency in critically ill patients","volume":"353","author":"Beishuizen","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.iac.2015.04.004_bib9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1749-6632.2011.06387.x","article-title":"Hyper-IgE syndrome update","volume":"1250","author":"Sowerwine","year":"2012","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"10.1016\/j.iac.2015.04.004_bib10","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jaci.2006.02.005","article-title":"The Wiskott-Aldrich syndrome","volume":"117","author":"Ochs","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2015.04.004_bib11","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/ajh.20789","article-title":"Non-small-cell lung cancer associated with excessive eosinophilia and secretion of interleukin-5 as a paraneoplastic syndrome","volume":"82","author":"Pandit","year":"2007","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.iac.2015.04.004_bib12","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/1097-0142(19910801)68:3<543::AID-CNCR2820680317>3.0.CO;2-3","article-title":"Blood and bone marrow eosinophilia in malignant tumors. Role and nature of blood and tissue eosinophil colony-stimulating factor(s) in two patients","volume":"68","author":"Stefanini","year":"1991","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.iac.2015.04.004_bib13","doi-asserted-by":"crossref","first-page":"893","DOI":"10.7326\/0003-4819-25-6-893","article-title":"Eosinophilia in malignant tumors: its significance","volume":"25","author":"Isaacson","year":"1946","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.iac.2015.04.004_bib14","first-page":"157","article-title":"Tissue eosinophilia in head and neck squamous neoplasia: an update","volume":"36","author":"Jain","year":"2014","journal-title":"Exp Oncol"},{"issue":"2","key":"10.1016\/j.iac.2015.04.004_bib15","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1053\/j.seminhematol.2012.01.003","article-title":"Lymphoproliferative disorders associated with hypereosinophilia","volume":"49","author":"Roufosse","year":"2012","journal-title":"Semin Hematol"},{"key":"10.1016\/j.iac.2015.04.004_bib16","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJM199910073411503","article-title":"Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia","volume":"341","author":"Simon","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.iac.2015.04.004_bib17","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.iac.2007.07.002","article-title":"Lymphocytic variant hypereosinophilic syndromes","volume":"27","author":"Roufosse","year":"2007","journal-title":"Immunol Allergy Clin North Am"},{"issue":"1","key":"10.1016\/j.iac.2015.04.004_bib18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jaci.2010.03.035","article-title":"Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence","volume":"126","author":"Crane","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.iac.2015.04.004_bib19","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1182\/blood-2004-03-0787","article-title":"FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia","volume":"104","author":"Pardanani","year":"2004","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.iac.2015.04.004_bib20","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.leukres.2005.11.011","article-title":"FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature","volume":"30","author":"Pardanani","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.iac.2015.04.004_bib21","series-title":"World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues","first-page":"68","article-title":"Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1","author":"Bain","year":"2008"},{"key":"10.1016\/j.iac.2015.04.004_bib22","series-title":"WHO classification of tumours of the haematopoietic and lymphoid tissues","first-page":"51","article-title":"Chronic eosinophilic leukemia, not otherwise specified","author":"Bain","year":"2008"},{"issue":"3","key":"10.1016\/j.iac.2015.04.004_bib23","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaci.2012.02.019","article-title":"Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes","volume":"130","author":"Valent","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2015.04.004_bib24","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A\u00a0tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.iac.2015.04.004_bib25","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood-2003-05-1627","article-title":"CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy","volume":"102","author":"Pardanani","year":"2003","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.iac.2015.04.004_bib26","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/sj.leu.2404662","article-title":"Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma","volume":"21","author":"Metzgeroth","year":"2007","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.iac.2015.04.004_bib27","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1038\/leu.2008.287","article-title":"Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias","volume":"22","author":"Gotlib","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.iac.2015.04.004_bib28","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/ng0198-84","article-title":"FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13 leukaemia\/lymphoma syndrome","volume":"18","author":"Xiao","year":"1998","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.iac.2015.04.004_bib29","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.iac.2015.04.004_bib30","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.iac.2015.04.004_bib31","first-page":"9","article-title":"Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate","volume":"3","author":"Schaller","year":"2001","journal-title":"MedGenMed"},{"issue":"9317","key":"10.1016\/j.iac.2015.04.004_bib32","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(02)08505-7","article-title":"Treatment of hypereosinophilic syndrome with imatinib mesylate","volume":"359","author":"Gleich","year":"2002","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.iac.2015.04.004_bib33","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1182\/blood-2003-01-0081","article-title":"Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.iac.2015.04.004_bib34","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1182\/blood-2007-07-100164","article-title":"Relapse following discontinuation of imatinib mesylate therapy for FIP1L1\/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing","volume":"110","author":"Klion","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.iac.2015.04.004_bib35","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/MD.0b013e3182a71eba","article-title":"The spectrum of FIP1L1-PDGFRA-associated chronic eosinophilic leukemia: new insights based on a survey of 44 cases","volume":"92","author":"Legrand","year":"2013","journal-title":"Medicine"},{"issue":"3","key":"10.1016\/j.iac.2015.04.004_bib36","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/ajh.23664","article-title":"World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management","volume":"89","author":"Gotlib","year":"2014","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.iac.2015.04.004_bib37","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/onc.2010.476","article-title":"The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in\u00a0vitro","volume":"30","author":"von Bubnoff","year":"2011","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.iac.2015.04.004_bib38","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/sj.bmt.1705437","article-title":"Allogeneic bone marrow transplantation for hypereosinophilic syndrome: long-term follow-up with eradication of FIP1L1-PDGFRA fusion transcript","volume":"38","author":"Halaburda","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.iac.2015.04.004_bib39","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/leu.2012.8","article-title":"Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases","volume":"26","author":"Lierman","year":"2012","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.iac.2015.04.004_bib40","doi-asserted-by":"crossref","first-page":"922","DOI":"10.3324\/haematol.2010.036558","article-title":"The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia\/lymphoma and t(7;8)(q22;p11)","volume":"96","author":"Wasag","year":"2011","journal-title":"Haematologica"},{"issue":"40","key":"10.1016\/j.iac.2015.04.004_bib41","doi-asserted-by":"crossref","first-page":"14479","DOI":"10.1073\/pnas.0404438101","article-title":"PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder","volume":"101","author":"Chen","year":"2004","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"9","key":"10.1016\/j.iac.2015.04.004_bib42","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1182\/blood-2003-07-2393","article-title":"Serum concentration of cardiac troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes","volume":"102","author":"Pitini","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.iac.2015.04.004_bib43","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00277-014-2221-y","article-title":"Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes","volume":"94","author":"Schwaab","year":"2015","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.iac.2015.04.004_bib44","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/bjh.12963","article-title":"Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities?","volume":"166","author":"Bain","year":"2014","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.iac.2015.04.004_bib45","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/sj.leu.2404266","article-title":"FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation","volume":"20","author":"Vu","year":"2006","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.iac.2015.04.004_bib46","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1182\/blood-2011-03-343426","article-title":"Response of ETV6-FLT3-positive myeloid\/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3","volume":"118","author":"Walz","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.iac.2015.04.004_bib47","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00277-013-1843-9","article-title":"Successful allogeneic stem cell transplantation with long-term remission of ETV6\/FLT3-positive myeloid\/lymphoid neoplasm with eosinophilia","volume":"93","author":"Chonabayashi","year":"2014","journal-title":"Ann Hematol"},{"issue":"10","key":"10.1016\/j.iac.2015.04.004_bib48","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1038\/leu.2014.168","article-title":"ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant","volume":"28","author":"Falchi","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.iac.2015.04.004_bib49","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.jaci.2009.09.022","article-title":"Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy","volume":"124","author":"Ogbogu","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2015.04.004_bib50","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3109\/10428194.2012.731602","article-title":"Diversity of clinical manifestations and response to corticosteroids for idiopathic hypereosinophilic syndrome: retrospective study in 33 patients","volume":"54","author":"Helbig","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.iac.2015.04.004_bib51","doi-asserted-by":"crossref","first-page":"78","DOI":"10.7326\/0003-4819-97-1-78","article-title":"The idiopathic hypereosinophilic syndrome: clinical, pathophysiologic, and therapeutic considerations","volume":"97","author":"Fauci","year":"1982","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.iac.2015.04.004_bib52","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000085560","article-title":"Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis","volume":"114","author":"Butterfield","year":"2005","journal-title":"Acta Haematol"},{"issue":"9","key":"10.1016\/j.iac.2015.04.004_bib53","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/cncr.23018","article-title":"PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study","volume":"110","author":"Jabbour","year":"2007","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.iac.2015.04.004_bib54","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa070812","article-title":"Treatment of patients with the hypereosinophilic syndrome with mepolizumab","volume":"358","author":"Rothenberg","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.iac.2015.04.004_bib55","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1158\/1078-0432.CCR-08-1302","article-title":"Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia","volume":"15","author":"Verstovsek","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.iac.2015.04.004_bib56","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2003-08-2798","article-title":"Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome","volume":"103","author":"Klion","year":"2004","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.iac.2015.04.004_bib57","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1365-2141.2008.07294.x","article-title":"Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study","volume":"143","author":"Metzgeroth","year":"2008","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.iac.2015.04.004_bib58","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2008.07033.x","article-title":"A\u00a0single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients","volume":"141","author":"Helbig","year":"2008","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.iac.2015.04.004_bib59","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3324\/haematol.11420","article-title":"The efficacy of imatinib mesylate in patients with FIP1L1-PDGFR -positive hypereosinophilic syndrome. Results of a multicenter prospective study","volume":"92","author":"Baccarani","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.iac.2015.04.004_bib60","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1182\/blood-2006-10-050054","article-title":"Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia","volume":"109","author":"Jovanovic","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.iac.2015.04.004_bib61","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s12185-012-1141-7","article-title":"Response to imatinib mesylate in patients with hypereosinophilic syndrome","volume":"96","author":"Arefi","year":"2012","journal-title":"Int J Hematol"},{"issue":"1","key":"10.1016\/j.iac.2015.04.004_bib62","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2006-05-024828","article-title":"Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders","volume":"109","author":"David","year":"2007","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.iac.2015.04.004_bib63","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1182\/blood-2014-02-555607","article-title":"Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib","volume":"123","author":"Cheah","year":"2014","journal-title":"Blood"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856115000314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856115000314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T14:53:38Z","timestamp":1537455218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856115000314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0889856115000314"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2015.04.004","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eosinophilia in Hematologic Disorders","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2015.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}